Glenn Coleman: Yes. So I’ll take that one. We’re not going to give specific guidance by segment. I did give some color though in my prepared remarks. So in orthodontics, we’re projecting to have low single-digit growth or single-digit growth. Obviously, that’s a slowdown from what we saw the past 5 quarters. It’s a combination of the macro environment for SureSmile and also Byte and some likely pressures we’re going to see with the student loan repayments being put back in place. And so we’re being a bit more cautious on ortho, although we still expect to see growth in the fourth quarter. We expect to see very strong growth out of Wellspect, A lot of that driven from new products. So, close to 7% organic growth in the third quarter.
I mentioned double-digit growth here in the fourth quarter. So those are 2 segments that we expect to grow. When we look at CTS, we were down about 4.5% or so in the third quarter, modeling something probably pretty consistent with that as we go into Q4. So we’re not expecting really any improvement in the overall segment there. And then for EDS, again, we’re probably projecting to be flat, plus or minus a point there. So that just gives you some high-level color for the segments.
Unidentified Analyst: Helpful. And then just going off Kevin’s question on Henry Schein. Have you seen any change to the ordering patterns from the other distributors you work with?
Glenn Coleman: Yes, not yet. I think it’s still too early. I think over the next couple of weeks will play out and see how the other distributors purchasing may change. But right now, we haven’t seen any significant impact or shift in our business.
Operator: Our next question comes from Jeff Johnson with Baird. Jeff Johnson with Baird, your line is open. If you’re on you, please unmute yourself. Please stand by for our next question. Our next question comes from Justin Lin with William Blair. Hello, Justin Lin, if you’re on me, please unmute yourself.
Andrea Daley: Amy, can we go to the next question please?
Operator: Our next question comes from Jason Bednar with Piper Sandler.
Jason Bednar: Can you hear me okay?
Simon Campion: Yes.
Andrea Daley: We can. Thanks, Jason.
Jason Bednar: Great. I wanted to start on China. The growth there was pretty impressive. There obviously is still the anticorruption campaign that’s been underway across that market. Are there any areas where you’re feeling the effects from that campaign? Do you think that held back your growth at all, in any specific category or segment? Any challenges in interacting with doctors, training and education? And I guess, along the same lines, have you seen that situation get any better, has it improved here as we’ve gone August, September, October?
Glenn Coleman: Yes. I don’t think we’ve seen any change from the last several months, and we really haven’t seen an impact on our business to date. We were very happy with the performance in China. I mentioned the strong year-over-year growth of 20%. Implants actually grew 30% sequentially year-over-year, it almost doubled. So we had really strong implants performance, and we’re expecting to put up some very good growth here in the fourth quarter. I think one of the real positives though in China is our Implants business actually on a year-to-date basis is now positive. So we fully offset all of the pricing erosion from . And we’re seeing really strong momentum on the volume side for implants. So on the whole, China is doing well.
I would just say we see the same pressures though with our CTS business in China. So areas like imaging and some of the larger high-end equipment are down. And even with that, we’re putting up 20% growth here in the third quarter. So it’s not growth across the board. We are seeing some impact, like we’re seeing in many other markets around the higher-end equipment as an example. But very happy with what we’re seeing on implants and overall performance in China.
Simon Campion: I would just add to that. We’ve — I think I spoke before about we rolled out a new code of business conduct here at Dentsply Sirona. We’re over 99.5% compliant to that internally now. And Asia Pacific, which obviously includes China, is 100% compliant to that. So we said when we arrived here, we would take ethics, compliance very seriously, and we’ve rolled that out, and the Chinese are also required to take that training on our behalf as well.
Jason Bednar: All right. Very helpful. For my other question, my follow-up here, there’s plenty of evidence out there, adult orthodontics is pretty pressured right now. We’ve heard from your peers same thing on this topic over the past week. Your Orthodontic business is holding up, I’d say, relatively well. But Glenn, you talked about a little bit of a softer outlook in 4Q. We think about the investments you’ve been making in this category to stimulate growth. I’m just trying to put this all together and love to hear where you see the market and your business, again, the adult orthodontic part of the market, going over the next 12 to 18 months, given these elements, the macro, the student loan repayment situation restarting, SmileDirect filing for bankruptcy. Just how do you see that part of the market right now?
Simon Campion: So let me jump in first and Glenn can get into some specifics, Jason. In relation to SureSmile, we just launched the SureSmile Simulator. So we continue to innovate in those areas as well. That has gone very well. Our initial rollout is suggesting that treatment acceptance is up with respect to SureSmile because of this simulator. And we also are in pilot with the Byte Plus program as well. So that has been well received by our pilot customers. So from an innovation and engagement perspective, we’re doing well. Our NPS scores are up, particularly on the Byte program. And I’ll hand it over to Glenn to deal with some of the specifics of your question.
Glenn Coleman: I think when we look at the intermediate and longer term, this is a very attractive market, the fastest-growing area in dentistry. So we still see it as a strong mid-teens growth type market for us over the long term. The short-term situation, we’re just being very cautious given the macro environment, given what we’re seeing with student loans and what that’s going to mean to our direct-to-consumer business. And obviously, we look at the SmileDirect Club as an opportunity. So we’ll see what happens there with respect to their bankruptcy announcement and what ultimately we could get from that. But right now, we’re being cautious going into the fourth quarter, which I think is prudent just given the macro environment and some other things that we’re seeing. But again, this is a top focus for us and an area that we think we can grow consistently in the double-digit range once we move past some of these acute pressures we’re seeing in the short term.
